Britain’s Frontier Pharma and the Baystone investment group have acquired Serbian pharmaceuticals company Zdravlje Leskovac, its owner’s Serbia-based business said in a statement on Monday.
The statement did not specify the price paid for the takeover of the drugmaker, which is owned by Actavis, a subsidiary of Israeli company Teva.
Teva took control of Zdravlje Leskovac through its acquisition of Actavis in 2016.
“Our intention is to closely cooperate with Teva during this transition and to … in time develop the (Zdravlje Leskovac) company,” the statement said, citing Levent Selamoglu, Frontier Pharma’s chairman.
Frontier Pharma is a UK-based speciality investor and pharmaceutical operator founded by Levent Selamoglu and Kiren Naidoo. The company has several decades of industry experience in Europe, Middle East and Africa (EMEA).
The group is well known for producing solid oral preparations, injections, and topical pharmaceutical forms, as well as API manufacturing and contracted to work with a number of multinational companies.
The Bayston Group is comprised of specialized pharmaceutical investors based in the UK and the US who are closely associated with the growth of SICOR and IVAKS Corp. The group is a major shareholder in Flynn Pharma (operating in the UK, Ireland and Germany) and has a portfolio of pharmaceutical investments including biotechnology and advanced drug delivery.
Actavis is the regional representative office of Teva for Serbia and Montenegro and one of the leading companies in the Serbian market.
Photo credits: Dmitry Kalinovsky/shutterstock
This post is also available in: Italiano